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Background: Paracetamol can be given both orally and intravenously (IV) with similar clinical efficacy, but the IV formulation 
is 360 times more expensive. IV paracetamol is therefore only recommended when the oral route is not available. This study 
investigated whether IV paracetamol was being used appropriately and whether there had been a change in prescribing 
patterns between 2008 and 2015 after the introduction and update of a prescribing protocol at an academic hospital complex 
in Bloemfontein, South Africa.
Methods: A retrospective comparative audit of patient files was undertaken. The prescribing and administration habits of IV 
paracetamol were compared for two consecutive months, seven years apart, including 88 and 83 patients, respectively, who had 
received IV paracetamol.
Results: IV paracetamol was administered appropriately in 37.5% of patients in 2008 and in 43.4% of patients in 2015 (p = 0.43). 
There was an improvement in the duration that IV paracetamol was prescribed for, which decreased from a median two days in 
2008 to one day (p < 0.01) in 2015. In total, 55 (32.4%) patients had a concomitant oral and IV paracetamol prescription, of which 
37 (21.6%) patients also received concomitant paracetamol administration. Twenty patients exceeded the 24-hour maximum 
dose. Seventeen patients weighed less than 40 kg; six of these patients (three paediatric and three adult) did not receive the 
correct weight adjusted dose of paracetamol, 15 mg/kg, resulting in excessive doses of paracetamol being administered (21–
32.3 mg/kg).
Conclusions: Patients are receiving IV paracetamol when the oral route is available; this is an unnecessary waste of money. 
Excessive doses of paracetamol were administered due to concomitant oral and IV paracetamol prescription and administration, 
and a failure to calculate dose of paracetamol according to body weight in low body weight patients. Further remedial 
interventions are therefore required.
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Introduction
Paracetamol is the most frequently used analgesic and antipyretic 
worldwide.1 It has been used widely for over 100 years and has a 
good safety record, with most problems occurring only if 
excessive doses are used.2,3 Paracetamol is a synthetic non-opioid 
drug acting on both peripheral and central pain pathways, with 
minimal anti-inflammatory properties.4–6
Various preparations of paracetamol exist which can be 
administered via several different routes—oral, rectal and 
intravenous (IV).7 The most commonly used route for 
administration is the oral route. Paracetamol administered via 
the oral route has a slower onset of analgesia (approximately 45 
minutes) when compared with the IV route (20 minutes), but 
thereafter the clinical effect is similar. The bioavailability of 
paracetamol when administered via the rectal route is 
approximately 60% and is the lowest among the several 
administration routes.8,9 Surgical patients expect effective and 
fast-acting pain relief. When the oral route of administration is 
not possible or rapid analgesia is needed, IV administration is the 
route of choice.10
Concerns have been raised that IV paracetamol is not always 
appropriately prescribed, as its use is associated with the 
following problems:11–14
•  increased relative costs (R0.10 per 1 gram (g) oral paraceta-
mol versus R36.48 per 1 g IV paracetamol) and nursing time;
•  potential for overdose with concomitant oral drugs contain-
ing paracetamol;
•  failure to adjust the dose according to body weight or other 
patient factors;
•  increased risk of infection with repetitive prolonged admin-
istration due to the IV cannula remaining in situ.
Acute pain management guidelines published in the United 
States and in the South African Society of Anaesthesiologists’ 
(SASA) South Africa Acute Pain Guidelines recommend the oral 
administration of drugs as soon as the patient is able to tolerate 
them.15,16 Obtaining an early switch from the IV to the oral route 
of administration of paracetamol in the management of pain 
therefore seems a reasonable step as both have been shown to 
be effective and safe, thus reducing the number of paracetamol 
injections per patient.
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Universitas Academic Hospital Complex (UAHC) is a tertiary 
hospital, located within central South Africa, Free State, 
Bloemfontein. IV paracetamol was first introduced to the hospital 
on 21 April 2008, with a paediatric dose only becoming available 
on 30 March 2011. A protocol for using IV paracetamol was first 
disseminated in 2008 in UAHC. A revision of the policy was made 
in 2014 and two addendums regarding important safety 
information were added in 2015.17 Within the various state 
hospitals in Bloemfontein, Pelonomi Hospital, which is also a 
tertiary hospital, has limited the use of IV paracetamol in that it 
may be prescribed only by an anaesthesiologist. UAHC has a 
protocol limiting the duration of IV paracetamol use to a 24-hour 
period or four doses. It may also only be prescribed by a specialist 
in the intensive care unit (ICU), anaesthesiology or theatre.
The primary objective of this study was to investigate whether IV 
paracetamol was being used appropriately at UAHC after the 
introduction of an IV paracetamol protocol in 2008, which was 
revised in 2015. Appropriate IV paracetamol use was defined as 
IV paracetamol prescribed to patients not able to receive or 
tolerate oral paracetamol, for the correct indication, at the 
correct dose, and for the correct duration. Secondary objectives 
included a review of the characteristics of the IV paracetamol 
prescriptions and a review of patients whose prescriptions 
exceeded the daily maximum dose of 4 grams.
Method
This study was a retrospective comparative audit. Two 
consecutive months were selected in two different years using a 
random number chart in order to be compared (June to July 
2008 and July to August 2015). The pharmacy was able to provide 
a list of patients who received IV paracetamol during these two-
month periods using the Meditech software system (https://ehr.
meditech.com/international/meditech-south-africa). Data were 
collected from patient records within the hospital archive. All 
patients who received a dose of IV paracetamol during the study 
period were included in the study. Patients excluded from the 
study were patients with incomplete or illegible medical records 
and patients not yet discharged from the hospital.
Data collected consisted of four components:
(1)  demographics: age, weight, gender, admission and dis-
charge date, admission diagnosis, ward and surgery type;
(2)  prescribing information: indication, dose, duration, adminis-
tration and concomitant paracetamol prescription;
(3)  IV administration information: dose and duration of 
administration;
(4)  clinical information: NPO/fasted, postoperative time to swal-
low, nasogastric tube in situ, and whether antiemetic medi-
cations were prescribed and administered.
Analysis was performed by the Department of Biostatistics, 
Faculty of Health Sciences, University of the Free State (UFS). 
Categorical variables were summarised as frequencies and 
percentages. Numerical variables were summarised as means 
and standard deviations or medians with interquartile ranges 
(IQR). The two time-periods were compared statistically using 
Mann–Whitney tests for numerical variables and chi-square or 
Fisher’s exact test for categorical variables. P-values ≤ 0.05 were 
considered statistically significant. A 95% confidence interval (CI) 
was calculated for the main outcome.
Results
During the combined four-month study period, a total of 469 1 g 
IV paracetamol bottles were issued to 278 patients. Incomplete 
records were found for 107 patients. A total of 171 patients, who 
received 290 bottles of IV paracetamol, were included in the 
study (Figure 1).
Patient characteristics are given in Table 1. The median patient 
age was 48.5 years in 2008 and 39 years in 2015. Paediatric vials 
of IV paracetamol were not available in 2008, but were available 
in 2015. In all, 18 paediatric patients received IV paracetamol, 11 
in 2008 (from adult vials) and seven in 2015. The patient weight 
and gender were similar between the two groups.
Figure 1: Flow diagram of identified, excluded and included records.
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The duration of hospital stay was similar between the two 
groups: a median of 10 days in 2008 and 8 days in 2015 (p = 0.29). 
The number of patients who underwent surgery was also similar 
between the two groups: 78 (88.6%) patients in 2008 and 77 
(92.8%) patients in 2015 (p = 0.08).
There was no significant difference in the IV paracetamol dose 
prescribed in mg/kg between the two groups (Table 2). In 2008, 
IV paracetamol was prescribed for a median of two days, which 
decreased to a median of one day in 2015 (p < 0.01). The duration 
of all IV analgesics prescribed also showed a decrease, from a 
median of three days to two days (p = 0.02).
There were 11 patients in 2008 and six patients in 2015 who had 
a weight of < 40 kg. Five of these patients in 2008, of whom three 
were paediatric patients, did not have the correct weight-
adjusted dose. In 2015, only one patient did not have the correct 
weight-adjusted dose. This resulted in doses of 21–32.3 mg/kg 
being administered to these patients.
As shown in Table 3, IV paracetamol was administered 
appropriately in only 33 (37.5%) patients in 2008 and 36 (43.4%) 
patients in 2015 with no significant difference between the year 
groups (95% CI –8.8%; 20.6%).
The six-hourly dosing frequency of IV paracetamol changed 
significantly between 2008 (n  =  79, 89.7%) patients and 2015 
(n = 60, 72.3%) patients (p < 0.01). An increase in the eight-hourly 
prescriptions was also observed from five (5.6%) patients in 2008 
to 21 (25.3%) patients in 2015.
There were 69 (78.4%) patients in 2008 and 72 (86.8%) in 2015 
who were able to swallow within 24 hours post-surgery (p = 0.03). 
Of the patients who could swallow within 24 hours, 48 (54.5%) 
patients in 2008 and 47 (56.6%) patients in 2015 received IV 
paracetamol.
Antiemetic medication was prescribed in 29 (33.0%) patients in 
2008 and 42 (50.6%) patients in 2015 (p  =  0.02). Forty (23.0%) 
patients had a nasogastric tube in situ and were receiving 
nasogastric fluids/feeds when they received a dose of IV 
paracetamol. Patients who had a nasogastric tube in situ while 
receiving IV paracetamol were located in the various ICUs 
(multidisciplinary, neurosurgical, surgical, paediatric and 
cardiothoracic) and the high care units—maternity high care 
and general high care.
Overall, 55 (32.2%) patients had two separate paracetamol 
prescriptions, 28 (31.9%) in 2008 and 27 (32.5%) in 2015. Of these 
separate paracetamol prescriptions, 37 (21.6%) patients also 
received a concomitant paracetamol administration on the same 
day—21 (23.8%) in 2008 and 16 (19.3%) in 2015. Twenty (11.7%) 
patients, nine (10.2%) in 2008 and 11 (13.3%) in 2015, exceeded 
the 24-hour maximum dose of 4 grams or 60 mg/kg/24 hours. 
Examples of patients who received a dose of paracetamol 
exceeding the maximum daily limit are given in Table 4.
A total of 95 (55.6%) patients received IV paracetamol for longer 
than 24 hours, 55 (62.5%) in 2008 and 40 (48.2%) in 2015. In 2008, 
all the wards had one or more prescriptions for IV paracetamol 
administered for a duration of greater than 24 hours. Wards with 
a prescription for a duration of greater than 24 hours in 2015 
were cardiothoracic, ICU (paediatric, multidisciplinary and 
neurosurgical), maternity high care, maternity, vascular, 
hepatobiliary, gastroenterology, ear, nose and throat, and plastic 
surgery.
In both year groups, the prescribing physician was mostly a 
registrar: 144 patients (84.2%) (Table 5).
Discussion
This audit has shown that IV paracetamol has been inappropriately 
prescribed and administered. The hospital complex has a 
protocol regarding the use of IV paracetamol and this study has 
demonstrated poor compliance with the appropriate use of IV 
paracetamol.
Reasons for the non-compliance of the IV paracetamol policy 
may be the following:
•  IV paracetamol is not being prescribed by specialists but by 
junior doctors:
 The pharmacy does not have the resources to monitor all IV 
paracetamol prescriptions. Clarity regarding a ‘specialist in thea-
tre’ as indicated in the protocol also remains uncertain.
•  Poor prescribing habits:
 Doctors may not be aware of the IV paracetamol protocol and 
are non-compliant.
 IV paracetamol scripts were written in such a manner that a 
patient could receive 3–4 doses for a 24-hour period, with no 
emphasis on the patient’s ability to tolerate oral liquids/food. 
This included the scripts for the perioperative period, protocols 
displayed for epidurals and patient-controlled analgesia pumps. 
This practice should be changed, emphasising that as soon as 
the patient can tolerate oral liquids/feeds that the administra-
tion of IV paracetamol be changed to oral paracetamol. (Most 
patients who were fasted perioperatively were able to tolerate 
oral liquids/feeds within 24 hours).
IV paracetamol is prescribed for a duration of greater than 24 
hours.
•  Convenience of using IV paracetamol:
 Patients may be more satisfied after receiving IV paracetamol 
drug compared with an oral drug and placebo.18
•  The rectal route of administration is no longer used at UAHC 
when the oral route of administration is unavailable.
•  Increased doctor awareness of the availability of IV 
paracetamol.
A similar audit by Palmer et al.12 at a tertiary paediatric hospital in 
Australia was performed when IV paracetamol was introduced to 
the hospital. IV paracetamol was placed conditionally on the 
hospital formulary with prescribing rights limited to two senior 
clinicians and for restricted indications Despite the limited 
prescriber rights there were still deviations from the guidelines, 
which were not associated with adverse events. The strict 
compliance during the introductory period allowed the Drug 
Table 1: Characteristics of patients receiving intravenous (IV) 
paracetamol during 2008 and 2015
Note: IQR = interquartile range.
Demographic 
characteristics
2008 (N = 88) 2015 (N = 83) p-value
Median age in years (IQR) 48.5 (25–65) 39 (26–55) 0.16
Median weight in kg (IQR) 68 (46–83) 65 (55–82) 0.57
Gender: 0.57
 Male n (%) 42 (47.7) 36 (43.4) -
 Female n (%) 46 (52.3) 47 (56.6) -
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Use Council to extend prescribing rights to consultants and 
trainee anaesthetists with limited indications within the 
institution.
IV paracetamol is indicated as an antipyretic and analgesic for 
symptomatic relief of mild to moderate pain and is used on all 
levels of the World Health Organisation analgesic ladder.19,20 In a 
recent literature review of randomised clinical trials for acute 
postoperative pain, the data indicated that IV paracetamol is an 
effective analgesic across a variety of surgical procedures.21–26 
The absorption of orally administered paracetamol may be 
unreliable perioperatively, up to 72 hours postoperatively. This 
may be due to delayed gastric emptying from the patient being 
stressed, preoperative fasting, concomitant opioid 
administration, the long-lasting effects of anaesthesia and the 
surgery itself.27,28
All drugs that can be administered via the oral route, except 
those in a slow-release formulation, may be administered via a 
feeding tube.29–31 Emphasis should be made regarding 
administering oral paracetamol via the nasogastric tubes in the 
various ICUs. If a patient is able to absorb the nasogastric fluids/
feeds, they should tolerate nasogastric paracetamol. Some 
patients with poor absorption from the gastrointestinal tract 
may require prolonged use of IV paracetamol. Dedicated syringes 
should be used for nasogastric tubes that are labelled and cannot 
be used with the IV system.
In adults, paracetamol has a ceiling effect at a dose of 1 000 mg, 
so a further increase in the dose will not result in a further 
increase in analgesia, but will increase the side effects and 
potential for toxicity.32,33 Paracetamol has intermediate lipid 
solubility, therefore an increase in the patient’s body-fat 
proportion alters the distribution slightly. At present, there is no 
evidence that this alteration is significant or affects the analgesic 
and antipyretic efficacy. There is thus no rationale for more than 
1  g or two preparations (oral and IV) being prescribed 
concurrently.34
The Food and Drug Authority (FDA) issued a notice in 2014 
stating that all prescription drug products with more than 
325 mg of acetaminophen be discontinued in order to protect 
consumers from liver damage.35 Patients who had concomitant 
paracetamol prescription and administration had paracetamol 
prescribed under the various trade names (Perfalgan®, Panado® 
and Dolorol Forte®). Despite the prescribing doctor being 
familiar with the generic and trade names, the staff in the wards 
who administer the paracetamol may not be familiar with the 
various names. It should be emphasised that generic names and 
not trade names are used when prescribing any drugs, including 
IV paracetamol, in order to avoid concomitant administration. 
Prescriptions should also include the maximum daily dose and 
be for a limited duration.
Paracetamol is known to have a narrow therapeutic index. The 
objective of this study was not to assess the toxicity from 
paracetamol but to audit how IV paracetamol is prescribed and 
administered. Liver function was not assessed so the clinical 
impact of the higher than recommended doses prescribed is not 
known.
From this study, there is clearly confusion among prescribing 
doctors regarding the various appropriate dose-per-weight and 
dose-per-age schedules. The British National Formulary and 
Table 2: Intravenous (IV) paracetamol dose and duration of 
prescriptions and duration of all IV analgesics
  2008 (N = 88) 2015 (N = 83) p-value
Prescription 
characteristic








2 1–23 1 1–10 < 0.01
Duration of all IV 
analgesics pre-
scribed (days)
3 1–23 2 0–10 0.02
Table 3: Intravenous (IV) paracetamol prescription characteristics
Notes: IV = intravenous; GCS = Glasgow Coma Scale; NG = nasogastric; NPO = nil 
per os.
Characteristic 2008 (N = 88) 2015 (N = 83) p-value




Analgesia 73 (82.9) 78 (94.0)  
Pyrexia 8 (9.1) 2 (2.4)  
Analgesia and pyrexia 5 (5.7) 2 (2.4)  
Not documented 2 (2.3) 1 (1.2)  
Indication for IV adminis-
tration:
0.58
NPO (peri-operative) 73 (83.0) 73 (88.0)  
Emesis 3 (3.4) 4 (4.8)  
Unconscious (low GCS) 5 (5.7) 3 (3.6)  
Not documented 7 (7.9) 3 (3.6)  
IV frequency of adminis-
tration:
< 0.01
Stat (immediately) 3 (3.3) 2 (2.4)  
q4 h (4-hourly) 1 (1.4) 0 (0)  
q6 h (6-hourly) 79 (89.7) 60 (72.3)  
q8 h (8-hourly) 5 (5.6) 21 (25.3)  
Post-surgical time to 
swallow (hours):
0.03
≤ 6 32 (36.4) 36 (43.4)  
> 6 ≤ 12 9 (10.2) 17 (20.5)  
> 12 ≤ 24 28 (31.8) 19 (22.9)  
> 24 ≤ 48 9 (10.2) 10 (12.1)  
> 48 ≤ 72 6 (6.8) 0 (0)  
> 72 4 (4.6) 1 (1.2)  
IV was followed by oral 
paracetamol
74 (84.1) 75 (90.4) 0.22
Concomitant paracetamol 
prescription
28 (31.8) 27 (32.5) 0.92
Concomitant paracetamol 
administration
21 (23.9) 16 (19.3) 0.47
Daily max exceeded 
(4 g/24 hours)
9 (10.2) 11 (13.2) 0.54
Antiemetic prescribed 29 (33.0) 42 (50.6) 0.02
Antiemetic administered 25 (28.4) 29 (34.9) 0.36
NG in situ 22 (25.0) 18 (21.7) 0.61
Appropriate IV paraceta-
mol administration
33 (37.5) 36 (43.4) 0.43
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q4 h (4-hourly) 1 (1.4) 0 (0)  
q6 h (6-hourly) 79 (89.7) 60 (72.3)  
q8 h (8-hourly) 5 (5.6) 21 (25.3)  
Post-surgical time to 
swallow (hours):
0.03
≤ 6 32 (36.4) 36 (43.4)  
> 6 ≤ 12 9 (10.2) 17 (20.5)  
> 12 ≤ 24 28 (31.8) 19 (22.9)  
> 24 ≤ 48 9 (10.2) 10 (12.1)  
> 48 ≤ 72 6 (6.8) 0 (0)  
> 72 4 (4.6) 1 (1.2)  
IV was followed by oral 
paracetamol
74 (84.1) 75 (90.4) 0.22
Concomitant paracetamol 
prescription
28 (31.8) 27 (32.5) 0.92
Concomitant paracetamol 
administration
21 (23.9) 16 (19.3) 0.47
Daily max exceeded 
(4 g/24 hours)
9 (10.2) 11 (13.2) 0.54
Antiemetic prescribed 29 (33.0) 42 (50.6) 0.02
Antiemetic administered 25 (28.4) 29 (34.9) 0.36
NG in situ 22 (25.0) 18 (21.7) 0.61
Appropriate IV paraceta-
mol administration
33 (37.5) 36 (43.4) 0.43
26 Southern African Journal of Anaesthesia and Analgesia 2018; 24(1):22–28
Kingdom Medicines and Healthcare Products Regulatory Agency 
(MHRA) has indicated that only 50 ml with 500 mg vials is to be 
used in patients weighing less than 33 kg.37,38
An audit on the use of IV paracetamol in infants under one year 
of age in the United Kingdom and Ireland demonstrated that 
paracetamol dosing is frequently above the licensed dose and is 
outside the licenced age range, but is in keeping with 
pharmacokinetic studies.39
During the total audit period, at least 102 patients were 
administered 174 bottles of IV paracetamol inappropriately. This 
amounts to a cost of R6 333.60 (R36.48/1 g), with the equivalent 
cost of oral paracetamol being R17.40 (R0.10/1 g). Additional to 
the extra cost of the ampoules of the IV paracetamol is the cost 
of maintaining the IV cannula, nursing staff and monitoring the 
infusion.
Limitations
This study was a retrospective audit, relying on patient records. 
Many patients were excluded due to the poor quality of patient 
records (38% of the IV bottles issued from the pharmacy had 
inadequate records for inclusion in the study).
Only prescribing and administration information was audited, 
not the actual clinical impact of patients at risk for potential 
overdose. Despite the introduction and dissemination within the 
SASA Acute Pain Guidelines recommend the maximum daily 
infusion doses listed in Table 6.5,36
It is recommended that the dose be decreased to 15 mg/kg in 
adults weighing less than 50 kg. Due to the potential for toxicity 
with using the 1 g in 100 ml vial of IV paracetamol, the United 











of the combination 
of drugs
Yes 3 19 1.3 68.4 1 Perfalgan® & Dolorol 
Forte®
Yes 12 35 4 114.2 1 Perfalgan & Dolorol 
Forte®
Yes 12 77 6 78 1 Perfalgan® & Dolorol 
Forte®
Yes 12 55 5.1 93 1 Perfalgan® & Panado®
Yes 22 40 5 125 2 Perfalgan® & Panado®
Yes 26 100 7 70 1 Perfalgan® & Panado®
Yes 27 52 4.5 86.5 3 Perfalgan® & Dolorol 
Forte®
Yes 38 92 5 54.3 1 Perfalgan® & Panado® 
syrup
Yes 38 88 5 56 1 Perfalgan® & Panado®
Yes 38 88 6 68 2 Perfalgan® & Panado®
Yes 54 58 5 86 1 Perfalgan® & Dolorol 
Forte®
Yes 40 58 5 86.2 1 Perfalgan® & Panado®
Yes 44 66 5 76 1 Perfalgan® & Panado®
Yes 51 99 5 50 1 Perfalgan® & Dolorol 
Forte®
Yes 53 60 8 133.3 2 Perfalgan® & Dolorol 
Forte®
Yes 54 43 5 116.2 5 Perfalgan® & Dolorol 
Forte®
Yes 58 120 6 50 2 Perfalgan® & Perfal-
gan®
No 64 60 7 117 1 Perfalgan® & Dolorol 
Forte®
Table 5: Rank of the doctor prescribing intravenous (IV) paracetamol 
and rank of doctors who prescribed IV paracetamol for a duration of > 
24 hours
Factor 2008 2015 p-value
Rank of doctor n (%) n (%)
Prescribed IV paracetamol: (n = 88) (n = 83) < 0.01
Intern 4 (4.5) 8 (9.6)  
Medical Officer 13 (14.8) 1 (1.2)  
Registrar 71 (80.7) 73 (88.0)  
Consultant 0 1 (1.2)  
Prescribed IV paracetamol for a dura-
tion of > 24 hours:
(n = 55) (n = 40) 0.02
Intern 1 (1.8) 3 (7.5)  
Medical Officer 10 (18.2) 1 (2.5)  
Registrar 43 (78.2) 36 (90.0)  
Consultant 1 (1.8) 0 (0)  
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hospital regarding the IV paracetamol prescribing protocol, no 
training was initiated regarding these updates.
Patients’ records for the dosing administration intervals were not 
monitored, i.e. whether a paracetamol dose was administered 
within four hours of the previous paracetamol dose. Only the 24-
hour total dose of paracetamol was monitored. IV paracetamol 
that was administered intraoperatively was also not monitored 
or compared with when the next dose of paracetamol was 
received in the ward.
Conclusion
IV paracetamol is not being used appropriately, as the guidelines 
regarding its use are not being adhered to. The implications of 
inappropriate IV paracetamol use can be divided into the 
following categories:
•  potential for patient overdose (concomitant 
administration);
•  economic implications to the hospital.
Additional training regarding the appropriate use of IV 
paracetamol should be given to the relevant prescribing staff. 
Protocols with the various dosing schedules according to age 
and weight should be visually displayed in common prescribing 
areas. In order to avoid concomitant paracetamol administration, 
prescriptions for paracetamol and all drugs should be done 
using the generic name and not the trade name. This will avoid 
confusing ward staff who administer paracetamol with all the 
various trade names. Prescriptions should include the daily 
maximum dose of paracetamol and emphasise the need to stop 
the IV route of administration as soon as the patient can tolerate 
oral liquids/feeds. Standard anaesthetic practice should entail 
documenting on the ward prescription when a dose of IV 
paracetamol was administered intraoperatively and when the 
next dose can be administered in the ward.
Authors’ contributions – N.J.P. was the main researcher, completing 
the project for his MMed (Anaesthesiology) degree. He developed 
the protocol, did the data collection for this study and wrote up 
the research. G.L. provided supervision and guidance. G.J. 
assisted with the protocol development, data analysis, 
interpretation and write-up.
Ethics approval – This study was approved by the Ethics 
Committee of the Faculty of Health Sciences of UFS (ECUFS 
143/2015). Permission was also obtained from the Free State 
Department of Health Research Council (FS 2015RP59 690).
Table 6: Intravenous (IV) paracetamol dosing guidelines5,36
  Dose of IV paracetamol (per 
infusion administration)
Interval between each 
administration
Maximum daily infusion dose
Preterm neonates > 32 weeks’ postmen-
strual age (controversial)
7.5 mg/kg 8 hours 25 mg/kg
Term, newborn, infants, toddlers and 
children weighing < 10 kg
7.5 mg/kg 4–6 hours 30 mg/kg
Children weighing 10–33 kg 15 mg/kg 4–6 hours 60 mg/kg
Children, adolescents and adults weigh-
ing 33–50 kg
15 mg/kg 4–6 hours 60 mg/kg
Adolescents and adults weighing > 
50 kg
1 g 4–6 hours Must not exceed 4 g
Intravenous paracetamol — waste not, want not
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